Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Anti-Interleukin Biologics for the treatment of the Atopic March Diseases

View through CrossRef
The atopic march refers to the natural history of allergic disorders as they develop from infancy to childhood. Classically, the atopic march begins with atopic dermatitis (AD), followed by food allergy, advancing to asthma, allergic rhinitis (AR), and finally to the fifth member eosinophilic esophagitis. The pathogenesis of the atopic march is complex, and involves genetic, immunological, and environmental factors. T helper type 2 (Th2) lymphocytes, and epithelial cells play a key role in the pathogenesis of the diseases in the atopic march. Th2 cells secrete cytokines, such as interleukin-5 (IL-5), IL-4, and IL-13, whereas, epithelial cell injury release alarmin cytokines, including IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). Th2 cells and alarmin cytokines play an important role in the development of eczematous skin lesions, airway inflammation and remodeling, and oesophageal mucosal inflammation. Treatment of eosinophilic asthma and associated comorbid disorders is challenging, and requires a precision targeted approach with biologics. Dupilumab is a fully humanized IgG4 monoclonal antibody to the IL-4Rα, which mediates signaling to both IL-4 and IL-13, and blocks their immunopathological effects. Dupilumab is the only biologic that has been approved for the treatment of eosinophilic asthma, AD, and eosinophilic esophagitis. In patients with eosinophilic asthma treatment with dupilumab has been shown to improve asthma control, reduce exacerbations, and improve lung function. In patients with atopic dermatitis dupilumab has been demonstrated to improve the Eczema Area Severity Index (EASI) score, Investigator’s Global Assessment (IGA) response, SCORing Atopic Dermatitis (SCORAD) score, and the Peak Pruritus Numerical Rating (PNR) scale. Lebrikizumab and Tralokinumab (anti-IL-13) failed to show the expected results for the treatment of asthma, astoundingly, in several clinical trials they have been shown to significantly improvement EASI score, IGA response, SCORAD score, PNR scale, sleep architecture, and Dermatology Life Quality Index (DLQI). They have been granted First Tract Designation, and European Commission regulatory approval, respectively. Tezepelumab (anti-TSLP) is approved for the treatment of eosinophilic asthma, and has been shown to significantly reduce exacerbations, and improve asthma control, lung function, and HLQoL. However, tezepelumab did not meet the endpoints in phase II for the treatment of AD. Keywords: Atopic March; Atopic Dermatitis; Eosinophilic Asthma; Interleukin; Dupilumab; Tralokinumab
Title: Anti-Interleukin Biologics for the treatment of the Atopic March Diseases
Description:
The atopic march refers to the natural history of allergic disorders as they develop from infancy to childhood.
Classically, the atopic march begins with atopic dermatitis (AD), followed by food allergy, advancing to asthma, allergic rhinitis (AR), and finally to the fifth member eosinophilic esophagitis.
The pathogenesis of the atopic march is complex, and involves genetic, immunological, and environmental factors.
T helper type 2 (Th2) lymphocytes, and epithelial cells play a key role in the pathogenesis of the diseases in the atopic march.
Th2 cells secrete cytokines, such as interleukin-5 (IL-5), IL-4, and IL-13, whereas, epithelial cell injury release alarmin cytokines, including IL-25, IL-33, and thymic stromal lymphopoietin (TSLP).
Th2 cells and alarmin cytokines play an important role in the development of eczematous skin lesions, airway inflammation and remodeling, and oesophageal mucosal inflammation.
Treatment of eosinophilic asthma and associated comorbid disorders is challenging, and requires a precision targeted approach with biologics.
Dupilumab is a fully humanized IgG4 monoclonal antibody to the IL-4Rα, which mediates signaling to both IL-4 and IL-13, and blocks their immunopathological effects.
Dupilumab is the only biologic that has been approved for the treatment of eosinophilic asthma, AD, and eosinophilic esophagitis.
In patients with eosinophilic asthma treatment with dupilumab has been shown to improve asthma control, reduce exacerbations, and improve lung function.
In patients with atopic dermatitis dupilumab has been demonstrated to improve the Eczema Area Severity Index (EASI) score, Investigator’s Global Assessment (IGA) response, SCORing Atopic Dermatitis (SCORAD) score, and the Peak Pruritus Numerical Rating (PNR) scale.
Lebrikizumab and Tralokinumab (anti-IL-13) failed to show the expected results for the treatment of asthma, astoundingly, in several clinical trials they have been shown to significantly improvement EASI score, IGA response, SCORAD score, PNR scale, sleep architecture, and Dermatology Life Quality Index (DLQI).
They have been granted First Tract Designation, and European Commission regulatory approval, respectively.
Tezepelumab (anti-TSLP) is approved for the treatment of eosinophilic asthma, and has been shown to significantly reduce exacerbations, and improve asthma control, lung function, and HLQoL.
However, tezepelumab did not meet the endpoints in phase II for the treatment of AD.
Keywords: Atopic March; Atopic Dermatitis; Eosinophilic Asthma; Interleukin; Dupilumab; Tralokinumab.

Related Results

EVALUATION OF FOOD SENSITIVITY IN CHILDREN WITH ATOPIC DERMATITIS
EVALUATION OF FOOD SENSITIVITY IN CHILDREN WITH ATOPIC DERMATITIS
Objective: Atopic dermatitis is considered an important risk factor for the development of food allergies. This retrospective study aimed to evaluate food sensitivity in pediatric ...
The Course of Life of Patients with Childhood Atopic Dermatitis
The Course of Life of Patients with Childhood Atopic Dermatitis
Abstract:  Atopic dermatitis mainly covers the period of infancy to adulthood, an important period in the development of an individual. The impairment of quality of life and the ps...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Relation between Interleukin-6, Interleukin-10 and Interleukin-2 Receptor and mortality in Severely Ill COVID-19 patients
Relation between Interleukin-6, Interleukin-10 and Interleukin-2 Receptor and mortality in Severely Ill COVID-19 patients
Objective: To investigate the relation involving soluble interleukin-2 receptor, interleukin-6 and interleukin-10 in hospitalised patients with severe coronavirus disease-2019 infe...
Cell-Biological Analysis of Atopic Cataractous Lenses
Cell-Biological Analysis of Atopic Cataractous Lenses
The number of people suffering from atopic dermatitis, a recent social problem believed to have arisen from environmental pollution and changes, continues to increase today, and th...
Principles of complementary food introduction in atopic dermatitis
Principles of complementary food introduction in atopic dermatitis
Atopic dermatitis (AD) is one of the most common inflammatory skin disorders. In most patients, AD is a starting point for developing other atopic diseases, e.g., food allergy, all...
“Lavender Haze” in the Airways
“Lavender Haze” in the Airways
Introduction Taylor Swift has dominated global press in recent years through the success of her Eras Tour, her use of authenticity in branding (Khanal 234), and her choreographed e...

Back to Top